A global tobacco firm is aiming to generate billions of pounds from the diseases caused by smoking through deals with biotech companies for the exclusive rights to market future lung cancer vaccines.

Japan Tobacco, which makes Camel, Winston and Mild Seven and is the third biggest tobacco company in the world, believes that the arrival of a successful lung cancer vaccine on the market would encourage smokers to continue their habit in the belief that that the vaccine would prevent long term health problems.